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Introduction Metabolic syndrome (MetS) is deﬁned by metabo-
lic and cardio-vascular impairments and is frequently associated
with anxiety and depressive disorders. Both MetS and anxiety-
depressive syndromes feature similar systemic inﬂammatory
alterations. Inﬂammation of the large bowel is also a key factor
for the development of colorectal cancer (CRC).
Objective To measure the prevalence of MetS and symptoms of
anxiety and depression among patients undergoing colonoscopy.
Methods Cross-sectional study. Patientsundergoingcolonoscopy
aged 40 or more, with negative history for neoplasia or inﬂam-
matory bowel disease, were enrolled. Data collected: colonoscopy
outcome, presence/absence of MetS (IDF and ATP III criteria), pre-
sence/absence of depressive and anxiety symptoms assessed with
HADS.
Results The sample was made up of 53 patients (female 24,
45.3%).Mean agewas60.66±9.08. At least one adenomawas found
to 23 patients (43.3%). Prevalence of MetS ranged from 34% to 36%
(ATP III and IDF criteria, respectively). Prevalence of depressive and
anxiety symptoms was 20% and 33%, respectively.
Conclusion Prevalence of MetS, anxiety and depressive symp-
toms among patients undergoing colonoscopy was higher than in
the general population.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
http://dx.doi.org/10.1016/j.eurpsy.2017.02.236
EW0623
Impact of anxiety-depressive
symptoms on outpatients’ quality of
life: Preliminary results from an
Italian observational study
S. Tassi1, G. Rioli 2,∗, G. Mattei3, S. Ferrari4, G.M. Galeazzi4
1 Università degli studi di modena e Reggio Emilia, Corso di Laurea in
Medicina e Chirurgia, Modena, Italy
2 Università degli Studi di Modena e Reggio Emilia, Scuola di
Specializzazione in Psichiatria, Sassuolo, Italy
3 Università degli Studi di Modena e Reggio Emilia, Scuola di
Specializzazione in Psichiatria, Modena, Italy
4 Università degli Studi di Modena e Reggio Emilia, Dipartimento di
Medicina Diagnostica- Clinica e di Sanità Pubblica- sezione di
Psichiatria, Modena, Italy
∗ Corresponding author.
Introduction Several studies have shown an association between
theShort-Form36 (SF36) scoresandanxiety-depressive symptoms,
suggesting that depression in particular could reduce Quality of
Life (QoL) to the same, and even greater, extent than chronic non-
communicable diseases, such as diabetes and hypertension.
Aims Toexplore the relationship amongQoLandanxiety, depres-
sive and anxiety-depressive symptoms in an outpatient sample.
Methods Cross-sectional study. Inclusion criteria: outpatients
aged ≥40 years, without history for cancer, attending colono-
scopy after positive faecal occult blood test. Collected data: blood
pressure, blood glucose, lipid proﬁle. Psychometric test: Hospital
Anxiety and Depression Scale (HADS). QoL was assessed with SF36.
Statistics performed with STATA13.
Results 54 patients enrolled (27 females). Sixteen patients
(30.2%)were positive for anxiety symptoms, ten (18.9%) for depres-
sive symptoms and ﬁve (9.4%) for anxiety-depressive symptoms.
The perceived QoL was precarious in twelve subjects (22.2%): eight
(15.9%) had low score (≤ 42) at “Mental Component Summary”
(MCS) subscale, three (5.7%) at the “Mental Health” item and one
patient (1.9%) at the “Vitality” one. At the multiple regression
analysis, depressive (OR=28.63; P=0.01) and anxiety-depressive
symptoms (OR=11.16; P=0.02) were associated with MCS.
Conclusions The association emerging from the present study
between depressive/anxiety symptoms and the MCS component of
SF36 is consistent with available literature. Study design and small
sample size do not allow to generalize results, that need further
studies to be conﬁrmed.
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Patients with severe mental illness (SMI) have been described at
higher riskof cardiovasculardisease (CVD). Theaimof this systema-
tic reviewandmeta-analysiswas to quantify prevalence, incidence,
cross-sectional association and longitudinal increased risk of coro-
nary heart disease (CHD), stroke, transient ischemic attack and
cerebrovascular disease (CBVD), heart failure (HF), peripheral vas-
cular disease (PVD), death due to CVD, and any CVD in patients
with SMI. We included 92 studies, with a total population of
3,371,461 patients (BD=241,226, MDD=476,102, SCZ=1,721,586,
SMI =932,547) and 113,925,577 controls. Pooled prevalence of
any CVD in SMI was 9.9% (95% CI =7.4–13.3) (33 studies, 360,144
patients). Compared to controls, after adjusting for a median of 7
confounders, SMI was associated with higher risk of CVD in cross-
sectional studies, OR:1.53 (95% CI =1.27–1.83) (11 studies), with
CHD OR: 1.51 (95% CI =1.47–1.55) (5 studies), with CBVD OR: 1.42
(95%CI =1.21–1.66) (6 studies), and tended tobeassociatedwithHF
OR: 1.28 (95% CI =0.99–1.65) (4 studies). Cumulative incidencewas
3.6 CVD events in a median follow-up period of 8.4 years (range:
1.76–30). After considering a median of 6 confounders, SMI was
associated with higher longitudinal risk of CVD in longitudinal stu-
dies HR: 1.78 (95% CI =1.6, 1.98) (31 studies), of CHD: HR: 1.54 (95%
CI 1.30–1.82) (18 studies), of CBVD HR: 1.64 (95% CI 1.26–2.14) (11
studies), of HFHR:2.10 (95% CI 1.64–2.70) (2 studies), of PVD, unad-
justed RR: 3.11 (95% CI 2.46–3.91) (3 studies), of death due to CVD,
HR 1.85 (95% CI 1.53–2.24) (16 studies). In this meta-analysis, the
